SGLT1/2 Inhibitor Shows ' Spectacular ' Safety, Efficacy in T2D SGLT1/2 Inhibitor Shows ' Spectacular ' Safety, Efficacy in T2D

Sotagliflozin, a novel type of sodium-glucose cotransporter inhibitor, showed the diverse benefits this drug class provides along some new twists in a pair of international pivotal trials.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Cardiology News Source Type: news